IMAC (BACK) Competitors $0.03 0.00 (-1.58%) As of 10:25 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock BACK vs. BTTX, UPHL, ACONW, AONC, DHACW, LFMDP, OTRKP, PIIIW, TALKW, and TOIIWShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), Talkspace (TALKW), and Oncology Institute (TOIIW). These companies are all part of the "healthcare" industry. IMAC vs. Better Therapeutics UpHealth Aclarion American Oncology Network Digital Health Acquisition LifeMD Ontrak P3 Health Partners Talkspace Oncology Institute Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Is BTTX or BACK more profitable? Company Net Margins Return on Equity Return on Assets Better TherapeuticsN/A N/A N/A IMAC N/A N/A -325.44% Do insiders and institutionals have more ownership in BTTX or BACK? 34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 5.8% of IMAC shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by company insiders. Comparatively, 12.3% of IMAC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, BTTX or BACK? IMAC has higher revenue and earnings than Better Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBetter TherapeuticsN/AN/A-$39.76MN/AN/AIMAC$72.05K0.89-$9.42MN/AN/A Which has more volatility & risk, BTTX or BACK? Better Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, IMAC has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Does the MarketBeat Community prefer BTTX or BACK? Better Therapeutics received 5 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 41.67% of users gave Better Therapeutics an outperform vote while only 0.00% of users gave IMAC an outperform vote. CompanyUnderperformOutperformBetter TherapeuticsOutperform Votes541.67% Underperform Votes758.33% IMACOutperform VotesNo VotesUnderperform Votes1100.00% Does the media prefer BTTX or BACK? In the previous week, IMAC had 1 more articles in the media than Better Therapeutics. MarketBeat recorded 1 mentions for IMAC and 0 mentions for Better Therapeutics. Better Therapeutics' average media sentiment score of 0.00 beat IMAC's score of -0.15 indicating that Better Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Better Therapeutics Neutral IMAC Neutral SummaryBetter Therapeutics beats IMAC on 6 of the 10 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BACK vs. The Competition Export to ExcelMetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$64,000.00$1.22B$5.31B$8.42BDividend YieldN/A1.11%5.21%4.10%P/E RatioN/A7.8926.7819.69Price / Sales0.8915.77386.97118.34Price / CashN/A8.1038.2534.62Price / Book-0.050.766.744.50Net Income-$9.42M$36.27M$3.23B$248.32M7 Day PerformanceN/A-4.26%1.49%-0.03%1 Month PerformanceN/A9.61%11.47%12.72%1 Year PerformanceN/A-62.71%16.57%7.38% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BACKIMACN/A$0.03-1.6%N/A-99.1%$64,000.00$72,050.000.00180BTTXBetter TherapeuticsN/A$0.00flatN/A-99.1%$10,000.00N/A0.0040UPHLUpHealthN/A$0.00flatN/A-99.9%$4,000.00$130M0.001,750Gap UpACONWAclarionN/A$0.04-2.5%N/A+23.0%$0.00$45,724.000.007AONCAmerican Oncology NetworkN/A$6.00+2.6%N/A+258.8%$0.00$1.34B0.001,520Gap UpDHACWDigital Health AcquisitionN/A$0.04flatN/AN/A$0.00N/A0.00N/ALFMDPLifeMDN/A$24.69+2.9%N/A+16.5%$0.00$234.01M0.00230News CoverageOTRKPOntrakN/A$0.23flatN/A-26.7%$0.00$10.84M0.00250News CoverageGap DownPIIIWP3 Health PartnersN/A$0.01+31.8%N/A-82.6%$0.00$1.50B0.00500Positive NewsGap UpTALKWTalkspaceN/A$0.11-0.9%N/A-33.1%$0.00$194.36M0.00500Positive NewsGap DownTOIIWOncology InstituteN/A$0.07+9.1%N/A-22.2%$0.00$393.41M0.00660Positive NewsGap Up Related Companies and Tools Related Companies Better Therapeutics Competitors UpHealth Competitors Aclarion Competitors American Oncology Network Competitors Digital Health Acquisition Competitors LifeMD Competitors Ontrak Competitors P3 Health Partners Competitors Talkspace Competitors Oncology Institute Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BACK) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BACK Stock Free BACK Stock Alerts